Improvement of immune dysregulation in individuals with long COVID at 24-months following SARS-CoV-2 infection

SARS-CoV-2感染后24个月,长期新冠患者的免疫失调情况有所改善

阅读:14
作者:Chansavath Phetsouphanh ,Brendan Jacka ,Sara Ballouz ,Katherine J L Jackson ,Daniel B Wilson ,Bikash Manandhar ,Vera Klemm ,Hyon-Xhi Tan ,Adam Wheatley ,Anupriya Aggarwal ,Anouschka Akerman ,Vanessa Milogiannakis ,Mitchell Starr ,Phillip Cunningham ,Stuart G Turville ,Stephen J Kent ,Anthony Byrne ,Bruce J Brew ,David R Darley ,Gregory J Dore ,Anthony D Kelleher # ,Gail V Matthews #

Abstract

This study investigates the humoral and cellular immune responses and health-related quality of life measures in individuals with mild to moderate long COVID (LC) compared to age and gender matched recovered COVID-19 controls (MC) over 24 months. LC participants show elevated nucleocapsid IgG levels at 3 months, and higher neutralizing capacity up to 8 months post-infection. Increased spike-specific and nucleocapsid-specific CD4+ T cells, PD-1, and TIM-3 expression on CD4+ and CD8+ T cells were observed at 3 and 8 months, but these differences do not persist at 24 months. Some LC participants had detectable IFN-γ and IFN-β, that was attributed to reinfection and antigen re-exposure. Single-cell RNA sequencing at the 24 month timepoint shows similar immune cell proportions and reconstitution of naïve T and B cell subsets in LC and MC. No significant differences in exhaustion scores or antigen-specific T cell clones are observed. These findings suggest resolution of immune activation in LC and return to comparable immune responses between LC and MC over time. Improvement in self-reported health-related quality of life at 24 months was also evident in the majority of LC (62%). PTX3, CRP levels and platelet count are associated with improvements in health-related quality of life.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。